Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2024-04-22 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
拓新药业集团股份有限公司2023年募集资金年度存放与使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "募集资金年度存放与使用情况鉴证报告" which translates to "Annual Verification Report on the Storage and Use of Raised Funds" for the year 2023. It includes detailed information about the amount of funds raised, their storage, usage, changes in investment projects, and compliance with regulatory requirements. The document is issued by an accounting firm providing an attestation on the use of the raised funds, referencing regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The content focuses on the verification and reporting of fundraising capital usage rather than a full annual report or earnings release. This type of document is a standalone audit or verification report related to fundraising capital usage, fitting the category of Audit Report / Information (AR). The document length is substantial (over 14,000 characters) and contains detailed financial and compliance information, not merely an announcement or certification letter, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the best classification is AR (Audit Report / Information). FY 2023
2024-04-22 Chinese
2024年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2024 年第一季度报告" which translates to "2024 First Quarter Report". It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial changes for the first quarter of 2024. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the quarter. It also mentions that the report is unaudited, which is typical for interim or quarterly reports. The length of the document (over 13,000 characters) and the presence of substantive financial data confirm it is not merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-04-22 Chinese
关于使用闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the decision to use idle funds for cash management, including details on the amount, purpose, risk control, and approvals from the board and supervisory committee. It is a formal disclosure of a corporate action related to cash management and investment of idle funds, not a financial report or earnings release. The document is relatively short (2283 characters) and serves as a regulatory announcement about a corporate financing-related decision. It does not contain financial statements or detailed financial analysis. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including cash management activities.
2024-04-22 Chinese
关于购买董监高责任险的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's plan to purchase directors and officers liability insurance (董监高责任险). It details the insurance scheme, board and supervisory committee meetings, and the proposal to submit the matter to the shareholders' meeting for approval. The document is a formal announcement of a corporate governance-related matter, specifically about risk management and insurance for directors and senior management. It does not contain financial statements, audit results, or detailed financial data. It is not a report, earnings release, or regulatory certification. It is also not a management change announcement but relates to governance and risk management. Given the nature of the content, it fits best under Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2024-04-22 Chinese
中天国富证券有限公司关于拓新药业集团股份有限公司使用闲置自有资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed opinion and verification report from a sponsoring securities company regarding the use of idle funds by a listed company for cash management. It includes descriptions of the purpose, amount, investment types, risk analysis, board and supervisory approvals, and compliance with regulatory requirements. The document is not a full financial report but rather a regulatory compliance and verification statement related to a specific financial activity (cash management). It does not contain financial statements or earnings data, nor is it a brief announcement or a certification letter. This type of document fits best under 'Regulatory Filings' (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2024-04-22 Chinese
上市公司独立董事候选人声明与承诺-赵永德
Board/Management Information Classification · 95% confidence The document is a detailed declaration and commitment statement by an independent director candidate for a listed company. It includes multiple legal and regulatory compliance affirmations, qualifications, and commitments related to the candidate's independence and eligibility to serve as an independent director. There are no financial statements, earnings data, or report summaries. The content is focused on board/management information, specifically about a director candidate's qualifications and declarations. This fits the category of Board/Management Information (MANG), which covers announcements of changes or nominations in the company's board of directors or senior management.
2024-04-22 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.